Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Ernesto Fedele
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14499-14499
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies
Jifa Zhang, Yinglu Zhang, Jiaxing Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 129
Anti-Amyloid Therapies for Alzheimer’s Disease and Amyloid-Related Imaging Abnormalities: Implications for the Emergency Medicine Clinician
Megan A. Rech, Christopher R. Carpenter, Neelum T. Aggarwal, et al.
Annals of Emergency Medicine (2025)
Closed Access | Times Cited: 1
The impact of genetic variability on Alzheimer’s therapies: obstacles for pharmacogenetic progress
Ramón Cacabelos, Olaia Martínez-Iglesias, Natalia Cacabelos, et al.
Expert Opinion on Drug Metabolism & Toxicology (2025), pp. 1-28
Closed Access | Times Cited: 1
Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review
Semira Abdi Beshir, Nadia Hussain, Vineetha Bharathan Menon, et al.
International Journal of Alzheimer s Disease (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 6
Biofilm-camouflaged Prussian blue synergistic mitochondrial mass enhancement for Alzheimer's disease based on Cu2+ chelation and photothermal therapy
Lianxin Li, Yu Xiong, Yuewen Zhang, et al.
Journal of Controlled Release (2024) Vol. 375, pp. 269-284
Closed Access | Times Cited: 6
Ion transporter cascade, reactive astrogliosis and cerebrovascular diseases
Md Shamim Rahman, Rabia Islam, Mohammad Iqbal H. Bhuiyan
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Amin Mahmood Thawabteh, Aseel Wasel Ghanem, Sara AbuMadi, et al.
Molecules (2024) Vol. 29, Iss. 21, pp. 5131-5131
Open Access | Times Cited: 5
Natural products targeting amyloid-β oligomer neurotoxicity in Alzheimer's disease
Priscila Baltazar Gonçalves, Ana Carolina Rennó Sodero, Yraima Cordeiro
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116684-116684
Closed Access | Times Cited: 4
A philosophy of science approach to the amyloid hypothesis of Alzheimer's disease
Timothy Daly
European Journal of Neuroscience (2024) Vol. 60, Iss. 5, pp. 4707-4722
Open Access | Times Cited: 4
Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023
Alexander C. Martins, Mariana Y. Oshiro, Fernando Alberício, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 1992-1992
Open Access | Times Cited: 4
Anticorpos anti-amiloide no tratamento da Doença de Alzheimer: uma revisão narrativa
Bruno Souza Fonseca, Matheus Henrique de Lima Cordeiro, P. Abreu, et al.
Revista Sociedade Científica (2025) Vol. 8, Iss. 1, pp. 197-203
Closed Access
Interplay between Oxidative Stress, Neuroinflammatory Cytokines and Melatonin in Alzheimer’s Disease: Insights from Cerebrospinal Fluid Analysis
Francisco Artime-Naveda, David Hevia, Rebeca Alonso‐Arias, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41841-e41841
Open Access
Proposed biological definitions of Parkinson's disease confuse understanding without delivering meaningful advances
Francisco Cardoso, Péter Schmidt
Journal of Parkinson s Disease (2025)
Open Access
Evolution of Alzheimer’s Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy
Emma Ortiz, Pedro Montes, Citlali Ekaterina Rodríguez-Pérez, et al.
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 128-128
Open Access
Protection against Amyloid-β Aggregation and Ferroptosis/Oxytosis Toxicity by Arylpyrazolones: Alzheimer’s Disease Therapeutics
Pedro Soares, Mizzanoor Rahaman, Pamela Maher, et al.
ACS Medicinal Chemistry Letters (2025)
Closed Access
The Impact of the Exposome on Alzheimer’s Disease: The Influence of Nutrition
Martina Monaco, Carola Torazza, Ernesto Fedele, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3015-3015
Open Access
Anticorps monoclonaux anti-amyloïde Beta contre la maladie d’Alzheimer en 2025 : prudence ou scepticisme ?
G Bouvenot
Bulletin de l Académie Nationale de Médecine (2025)
Closed Access
Multi-Target Inhibitor of ZJQ- 3 F Against AChE/BACE1/GSK3β Targets Improves the Cognitive Impairment of APP/PS1/Tau Triple-Transgenic Mouse Models of Alzheimer’s Disease
Nan Wang, Xinzhu Li, Xiaowen Jiang, et al.
Molecular Neurobiology (2025)
Closed Access
Anti-amyloid-beta treatments in Alzheimer’s disease: When neurologists turn into cheerleaders
Andi Olluri
Clinical Neurology and Neurosurgery (2024) Vol. 239, pp. 108237-108237
Closed Access | Times Cited: 3
Design, Synthesis, and Biological Evaluation of Imidazolylacetophenone Oxime Derivatives as Novel Brain-Penetrant Agents for Alzheimer’s Disease Treatment
Zhao-Yuan Bian, Peng‐Xiao Li, Xu-Yao Feng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 278, pp. 116794-116794
Closed Access | Times Cited: 3
Passive Anti-Amyloid Beta Immunotherapies in Alzheimer’s Disease: From Mechanisms to Therapeutic Impact
Thomas Gabriel Schreiner, Cristina Croitoru, Diana Nicoleta Hodorog, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1096-1096
Open Access | Times Cited: 2
Brain age as a biomarker for pathological versus healthy ageing – a REMEMBER study
Mandy Melissa Jane Wittens, Stijn Denissen, Diana M. Sima, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Coffee and Alzheimer's disease
Foad Mirzaei, Lila Agbaria, Khushbu Bhatnagar, et al.
Progress in brain research (2024), pp. 21-55
Closed Access | Times Cited: 2
From Plaques to Pathways in Alzheimer’s Disease: The Mitochondrial-Neurovascular-Metabolic Hypothesis
Sarah Kazemeini, Ahmed Nadeem-Tariq, Ryan M. Shih, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 21, pp. 11720-11720
Open Access | Times Cited: 2
Advancements in Neurodegenerative Diseases: Pathogenesis and Novel Neurorestorative Interventions
Wenyong Gao, Shiyuan Jing, Chao He, et al.
Journal of Neurorestoratology (2024), pp. 100176-100176
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top